Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd share price headed higher 6.66% to Rs 696.3 after the company's net profit saw a strong growth of 74.49% to Rs 28.46 crore, while revenue from operations slightly gained 9.37% to Rs 417.34 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, rising 4.13%. It has slipped by 0.73% over last one week and gained upto 0.56% in last one month while the market capitalization of Solara Active Pharma Sciences Ltd has improved by 7.90% and 23.88% in the same period respectively. Profit before tax (PBT) of Solara Active Pharma Sciences Ltd stood at Rs 28.46 crore in Q3 FY26, tumbling by 381.78% year-on-year, and expanding by 74.49% quarter-on-quarter. EBITDA came in at Rs 76 crore, rallying 122.84% YoY and surging by 28.71% sequentially. Total expenses saw a slight increase of 6.01% to Rs 367.14 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 217.8 crore, witnessing a sharp rise of 20.46% YoY, while employee benefits expense was at Rs 57.62 crore, easing 2.80% YoY. For the TTM ended FY26, revenue from operations tick up 6.64% to Rs 1368.98 crore, while net profit witnessed a sharp fall of 1472.22% to Rs 7.41 crore, compared to previous TTM. EBITDA surged by 19739% to Rs 180.59 crore, and PBT tanked by 1472.22% to Rs 7.41 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 152.91 crore in FY26, as against Rs 212.82 crore in FY25. Solara Active Pharma Sciences Ltd jumped 17.68% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 10.47% during the same period.

Solara Active Pharma Sciences Limited announced that there was no deviation or variation in the use of proceeds raised through a rights issue of Rs 446.62 crore in August 2026, according to a regulatory filing on Friday. The company’s audit committee approved a statement confirming the utilization of Rs 334.71 crore for repayment of borrowings and Rs 111.57 crore for general corporate purposes, with the remaining funds held in accounts for future use.

Solara Active Pharma Sciences Ltd share price inched up 1.92% to Rs 652.8 after the company's net profit soared by 74.49% to Rs 28.46 crore, while revenue from operations slightly gained 9.37% to Rs 417.34 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, gaining 4.13%. It has softened by 0.63% over last one week and crept higher by 0.66% in last one month while the market capitalization of Solara Active Pharma Sciences Ltd has marginally improved by 1.16% and 16.14% in the same period respectively. Profit before tax (PBT) of Solara Active Pharma Sciences Ltd stood at Rs 28.46 crore in Q3 FY26, crashing by 381.78% year-on-year, and rallying 74.49% quarter-on-quarter. EBITDA came in at Rs 76 crore, surging by 122.84% YoY and jumping 28.71% sequentially. Total expenses grew marginally by 6.01% to Rs 367.14 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 217.8 crore, witnessing a sharp rise of 20.46% YoY, while employee benefits expense was at Rs 57.62 crore, inching up 2.80% YoY. For the TTM ended FY26, revenue from operations inched higher 6.64% to Rs 1368.98 crore, while net profit tumbled by 1472.22% to Rs 7.41 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 19739% to Rs 180.59 crore, and PBT collapsed by 1472.22% to Rs 7.41 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 152.91 crore in FY26, as against Rs 212.82 crore in FY25. Solara Active Pharma Sciences Ltd rallied 12.54% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 10.04% during the same period.

Solara Active Pharma Sciences Limited announced the allotment of 8,300 equity shares following the exercise of options under its Solara Employee Stock Option Plan 2018, according to a filing with the BSE Limited and the National Stock Exchange of India Limited on Friday, October 16, 2026. The company’s paid-up share capital increased to Rs 48,16,99,569.00 following the allotment, which included 6,050 shares issued on June 28, 2024, and 2,250 shares issued on July 22, 2024, with an exercise price of Rs 375 per share.

Solara Active Pharma Sciences Limited will hold a board meeting on Friday, October 16, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited and the National Stock Exchange of India Limited. The trading window for dealing in the company's securities will be closed for designated persons from October 01, 2026, until 48 hours after the announcement of the financial results.

Solara Active Pharma Sciences Limited will close its trading window for securities transactions starting Thursday, October 1, 2026, and continuing for 48 hours after the announcement of financial results for the quarter and half year ending September 30, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Solara Active Pharma Sciences Limited announced the allotment of 2,250 equity shares following the exercise of options under its Solara Employee Stock Option Plan 2018, according to a filing with the BSE Limited and the National Stock Exchange of India Limited on August 18, 2026. The company's board approved the allotment, which was executed on June 28, 2024, and resulted in a paid-up share capital increase to Rs 48,05,79,964.50. The exercise price per share was Rs 375, generating Rs 8,43,750 for the company.

Net profit of Solara Active Pharma Sciences rose 55.04% to Rs 16.31 crore in the quarter ended June 2026 as against Rs 10.52 crore during the previous quarter ended June 2025. Sales rose 19.57% to Rs 381.60 crore in the quarter ended June 2026 as against Rs 319.15 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales381.60319.15 20 OPM %16.2417.87 - PBDT43.0234.10 26 PBT16.3110.52 55 NP16.3110.52 55 Powered by Capital Market - Live

Solara Active Pharma Sciences has appointed Ajit Manocha as Chief Information Officer (CIO) with effect from 10 August 2026.

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 23 July 2026.